ClinicalTrials.gg
Active, not recruitingNCT04865679REPOSE-XL℠Updated Jun 3, 2026

Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends

An interventional study of Axoguard Nerve Cap® in Symptomatic Neuroma, Amputation and Chronic Nerve Pain, sponsored by Axogen Corporation. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Axogen Corporation · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Peripheral Nerve Injuries with a site in United States — 10 open to participants now, 13 under way, 1 of them phase 3. Peripheral Nerve Injuries · United States.

Planned enrollment
16th of 21
15 · median 45
Started
2022
with 1 other
No phase
10 of 30
3 open now
Primary completion
2026-12
later than 2 of 12 live
Registered
19th of 30
by date
Lead sponsor
7 of 30
Axogen Corporation

Among the 30 studies in Peripheral Nerve Injuries with a site in United States, this one is the 16th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2022, is one of 10 with no phase, reaches primary completion later than 2 of the 12 other live ones, and was the 19th registered.

Peripheral Nerve Injuries

90 studies on the registry are indexed under Peripheral Nerve Injuries; 24 are open to participants now.

Browse Peripheral Nerve Injuries studies →

Open to participants now

10 of the 30 studies in Peripheral Nerve Injuries with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Peripheral Nerve Injuries studies recruiting now, 7 (39%) set no upper age limit and 7 (39%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Peripheral Nerve Injuries with a site in United States, or all of them as a file.
02

Study summary

This pilot study evaluates the tolerability and feasibility of the Axoguard Large-Diameter Nerve Cap (sizes 5-7 mm) for protecting and preserving terminated nerve endings after limb trauma or amputation when immediate attention to the nerve injuries is not possible.

03

Conditions studied

  • Symptomatic Neuroma
  • Amputation
  • Chronic Nerve Pain

Keywords

  • Peripheral Nerve Injuries
  • Peripheral Nervous System Disease
  • Neuroma
  • Nerve Pain
  • Nervous System Diseases
  • Trauma - Nervous System
  • Amputation
  • Nerve Repair
  • Surgical Treatment of Pain
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Potential Subjects MUST:

  1. Sign and date an IRB-approved written Form prior to initiation of any study procedures;
  2. Be an adult male or female ≥ 18 and ≤ 80 years of age;
  3. Present for surgery with either:

    1. Limb trauma and/or planned amputation of a limb and be candidates who are planned for a secondary nerve surgery such as Targeted Muscle Reinnervation (TMR) or Regenerative Peripheral Nerve Interface (RPNI) procedures within 6-12 months from time of amputation, or;
    2. A previous amputation and be undergoing surgery to address nerve ends;
  4. Have at least one nerve end measuring greater than 4 mm and less than 7 mm in diameter after debridement and hemostasis of the proximal nerve stump;
  5. Have sufficient soft tissue available to be adequately covered by the Axoguard Nerve Cap;
  6. Be willing and able to comply with all aspects of the treatment and follow-up assessments and to return for all required study visits throughout the study duration.

Exclusion Criteria: Potential Subjects MUST NOT:

  1. Currently undergoing or are expected to undergo treatment with chemotherapy, radiation therapy, or other known treatment that affects the growth of neural and/or vascular tissues;
  2. Have signs and symptoms of chemotherapy-induced peripheral neuropathy from previous chemotherapy;
  3. Be or have planned immunosuppressive therapy during the duration of the study;
  4. Current uncontrolled local or systemic infection as indicated by positive blood culture or other pathological indicators of infection;
  5. Be for soft tissue implants. This includes but is not limited to any pathology that would limit the blood supply to the target area or otherwise compromise healing;
  6. Have a of less than 15-months;
  7. Have a history of or be planning to undergo radiotherapy in the area of the end-neuroma;
  8. Have bony exostosis of the affected limb that is not treated at the time of nerve cap placement;
  9. Have uncontrolled Type 1 or Type 2 Diabetes Mellitus with of 8% or greater or those with diabetic neuropathy in the target area or proximal to the amputation site;
  10. Have a history of idiopathic neuropathy/radiculopathy, known sciatica or chronic back pain;
  11. Documented history of centralized nerve pain that does not respond to a peripheral nerve block in the affected limb;
  12. Have a known allergy to anesthetic agents;
  13. Have a known sensitivity to porcine-derived products;
  14. Be currently enrolled or have been enrolled in another interventional clinical research study within the past 30 days (at time of consent); or
  15. Be deemed unsuitable for inclusion in the study at the discretion of the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Axoguard Nerve Cap®

    Active Comparator: Porcine derived extracellular matrix (ECM) based Nerve Termination Device Implantation of appropriate diameter of Axoguard Nerve Cap® (sizes 5-7 mm) at the time of surgery

    Device: Axoguard Nerve Cap®

Interventions

  • DeviceAxoguard Nerve Cap®

    Entubulation of the nerve stump into the Axoguard Nerve Cap® following surgical excision of symptomatic neuroma

06

What researchers measure

Primary outcomes

  1. Safety: Adverse Events (AEs), Serious Adverse Events (SAEs), or Unanticipated Adverse Device Effects (UADEs)

    The primary safety endpoint will monitor the nature and incidence of AE's, SAE's and/or UADE's associated with an unplanned revision procedure prior to the planned Targeted Muscle Reinnervation (TMR) or Regenerative Peripheral Nerve Interface (RPNI) starting from implantation (operative day) through 15 months depending on whether or not the subject undergoes the secondary TMR or RPNI procedure.

    Time frame: 15 Months

Secondary outcomes

  1. Change in Visual Analog Scale (VAS) For Pain Score through TMR procedure or 12 post-operative months compared to baseline

    The Visual Analog Scale (VAS) For Pain is a patient reported outcomes scale whereby the patient indicates his/her current pain level by making a mark on a continuous horizontal 10-centimeter (100 millimeter) line. The distance from the 0 millimeter to the patient's mark corresponds to the amount of pain the subject is currently experiencing. VAS for Pain data are recorded as the number of millimeters from the left of the line to the patients mark across the range of 0-100 millimeters, with 0 millimeter representing no pain and 100 millimeters representing "the worst pain imaginable". Final VAS score will be collected either just prior to TMR or RPNI procedure or 12- months post op if subject will not undergo the secondary TMR or RPNI procedure

    Time frame: Week 2, 1, 3, 6, 9 and 12 months

  2. Change in Patient Reported Outcome Measurement Information System (PROMIS®) - Pain Related Measures through TMR or RPNI procedure or 12 post operative months compared to baseline

    The Patient Reported Outcome Measurement Information System (PROMIS®) - Pain Related Measures is a set of person-centered measures that evaluates and monitors a patient's physical health and pain. The pain related measures include domains evaluating fatigue, pain intensity, pain interference, sleep Disturbance, and Pain Behavior. Short forms containing fixed sets of 4-10 items or questions are included for each domain. All PROMIS scores are presented as T-scores where the T-score is the standardized score with a mean of 50 (range 20-80) and a standard deviation of 10. Higher scores indicate more of the concept being measured where sometimes the concept is desirable (e.g., physical function) and sometimes this it is undesirable (e.g., fatigue). Final PROMIS® Pain Related Measure will be collected either just prior to TMR or RPNI procedure or 12-months post op if subject will not undergo the secondary TMR or RPNI procedure.

    Time frame: Week 2, 1, 3, 6, 9 and 12 months

  3. Change in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) through TMR or RPNI procedure or 12 post-operative months compared to baseline

    In this study, the Work Productivity and Activity Impairment (WPAI:SHP) questionnaire is an instrument to measure impairments in both paid work and unpaid work (leisure/regular activities) due nerve injury post-surgical intervention. It measures (1) absenteeism (work time missed), (2) presenteeism (impairment at work / reduced on-the-job effectiveness), (3) work productivity loss (overall work impairment / absenteeism plus presenteeism), as well as the (4) impairments in unpaid activity because of nerve injury post-surgical intervention during the past seven days. Scores for these 4 measures are expressed as impairment percentages with higher percentage scores indicating greater impairment in than lower percentage scores. Final WPAI:SHP will be collected either at the office visit following the TMR or RPNI procedure or 12-months post op if subject will not undergo the secondary TMR or RPNI procedure

    Time frame: Week 2, 1, 3, 6, 9 and 12 months

  4. Change in Brief Activities Measure for Adults with Upper Limb Amputation (BAM-ULA) through 12 post-operative months compared to baseline

    The BAM-ULA is a 10-item observational measure of activity performance. The 10 items are as follows: tuck a shirt in pants, lift a 20-lb bag, open a water bottle, remove a wallet from back pocket, replace the wallet in back pocket, take a gallon of water from the refrigerator and place on the counter (lift gallon jug), pour water from a gallon jug, brush or comb hair, use a fork, and open a door with knob. Items are scored with either a 0 (cannot complete all subtasks) or 1 (can complete all subtasks). Lower scores area associated with greater impairment of activity performance and higher scores are associated with less impairment of activity performance.

    Time frame: 3, 6, 9 and 12 months

  5. Change in Timed Up and Go (TUG) Test for Lower Extremity Amputees through 12 post-operative months compared to baseline

    An observational test used to evaluate functional mobility in terms of postural stability, gait, stride length, and sway. Patients wear their regular footwear and can use a walking aid. They are asked to sit in a chair, stand up from that chair, walk to a line on the floor (10 ft. away) at their normal pace, turn around, walk back to the chair at a normal pace, and sit down again.

    Time frame: 3, 6, 9 and 12 months

  6. Change in the 10-Meter Walk Test (10 MWT) for Lower Extremity Amputees through 12 post-operative months compared to baseline

    A performance measure used evaluate functional mobility and gait. It assesses walking speed in meters per second over 10-meter distance.

    Time frame: 3, 6, 9 and 12 months

  7. Changes in quantity and class of pain medication use at week 2, 1, 3, 6, 9, 12, and 15 post-operative months comparted to baseline

    Quantity and class of pain medication use for subjects who were implanted with the Axoguard Nerve Cap® will be captured during the following visits: Screening (baseline), 2-weeks, 1, 3, 6, 9, 12, and 15 months post-op for comparison to baseline.

    Time frame: Week 2, 1, 3, 6, 9, 12, and 15 months

Other outcomes

  1. Nerve End Size Measurements

    Nerve end size as measured by MRI or CT scan prior to required secondary TMR or RPNI procedure recorded in cubic millimeters (mm3).

    Time frame: Prior to Secondary Surgery (if performed)

  2. Histological Assessment of Explanted Nerve Cap After Secondary Procedure

    Explanted tissue will be cut into thin slices, affixed to microscope slides, and stained with Hematoxylin and Eosin (H\&E), Masson's Trichrome (MT) and Neurofilament 200 (NF200) to allow for histological evaluation of axonal swirling, nerve cap remodeling, and overall tissue response.

    Time frame: Following Explant (if performed)

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2026, 57 months after the start.

Of 26 interventional studies with no phase under Peripheral Nerve Injuries, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 57. This study's planned 57 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2021
First posted
Apr 29, 2021
StartActual
Mar 2, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04865679
Lead sponsor
Axogen Corporation
Responsible party
Sponsor
First posted
Apr 29, 2021
Start date
Mar 2, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion